FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to a method for structural and/or functional improvement of arterioles in mammals with a pathology which is characterised by thickened walls of cerebral or renal arterioles involving introduction to said mammal of a peptide with an amino acid sequence D-W-F-K-A-F-Y-D-K-V-A-E-K-F-K-E-A-F (SEQ ID No. 5) or an inverted sequence F-A-E-K-F-K-E-A-V-K-D-Y-F-A-K-F-W-D (SEQ ID No. 444), in doses sufficient for structural and/or functional improvement of arterioles.
EFFECT: invention provides structural and/or functional improvement of arterioles and preserved functions of the essential target organs such as brain and kidneys.
20 cl, 2 ex, 29 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| PEPTIDE POSSESSING ABILITY TO RELIEVE AT LEAST ONE SYMPTOM OF INFLAMMATORY CONDITION, PHARMACEUTICAL COMPOSITION CONTAINING IT AND METHOD OF TREATING ATHEROSCLEROSIS WITH THEIR APPLICATION | 2005 |
|
RU2448977C2 |
| GLP-1 PEPTIDE HAVING ATTACHED OLIGOSACCHARIDE CHAIN | 2008 |
|
RU2539829C2 |
| PROCESS FOR PREPARATION OF GLYCOPEPTIDE HAVING SIALYLATED SUGAR CHAIN, AND METHOD FOR PRODUCING SIALYL GLYCOASPARAGINE | 2012 |
|
RU2586524C2 |
| GLYCATED PEPTIDE GLP-1 | 2009 |
|
RU2543157C2 |
| METHOD FOR PRODUCING PEPTIDE EXENATIDE | 2011 |
|
RU2458066C1 |
| PEPTIDE ANALOGUES GH-RH WITH OPPOSING ACTION, WAY OF DEPRESSION OF GH LEVEL, WAY OF DEPRESSION OF IGF-INIGF-II LEVEL, APPLICATION FOR INHIBITION OF GROWTH OF CANCER CELLS, PHARMACOLOGICALLY ACCEPTABLE COMPOSITION (VARIANTS) | 2004 |
|
RU2335506C2 |
| ANTAGONISTIC ANALOGUES OF GROWTH HORMONE RELEASING-HORMONE (GH-RH) INHIBITING INSULIN-LIKE GROWTH FACTORS (IGF-I AND -II) | 1999 |
|
RU2235099C2 |
| RGD-CONTAINING PEPTIDES | 2001 |
|
RU2214416C2 |
| GLP-1 ANALOGUE DERIVATIVE OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS AND THEREOF APPLICATION | 2010 |
|
RU2565536C2 |
| DUAL GLP1/GIP OR TRIGONAL GLP1/GIP/GLUCAGON AGONISTS | 2013 |
|
RU2652783C2 |
